BCAX

Bicara Therapeutics

Fundamental data last updated:April 13, 2026

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

Nasdaq

County of HQ

United States

Next Earnings Date

05/12/26

Business Summary

Bicara Therapeutics operates as a clinical-stage biotechnology company focused on developing targeted therapies, typically monetizing through drug development milestones, partnerships, and eventual commercialization of approved therapeutics. Cash generation is not driven by recurring revenue but by capital raises, licensing agreements, and the long-duration payoff of successful clinical programs. Its moat, if realized, would stem from proprietary molecules, intellectual property protection, and differentiated clinical data that create barriers to replication. In biotech, durable advantage comes from validated science and regulatory exclusivity, not scale economics—meaning value crystallizes only if its pipeline advances successfully through trials and regulatory approval.

VALUATION

P/E

-

Market Cap ($M USD)

$1,382

Forward P/E

-

PEG

-

PRICE TO SALES

-

PRICE TO BOOK

3.4

EV / EBITDA

-6.2

5-Year Average P/E

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

-$2.52

Next Year EPS Growth Estimate

-$3.04

Next Year Revenue Growth Estimate

-

Return on Equity (ROE)

-34.40%

Operating Margin

-

Debt-to-Equity

0

Piotroski F-Score

1

Altman Z-Score

26.8

Return on Invested Capital (ROIC)

-33.90%%

Current Ratio

14.6

Quick Ratio

Gainseekers Quantitative Analysis

Summary

BCAX screens as a pure balance-sheet story wrapped around a deeply unprofitable biotech core. With no P/E, no Forward P/E, and EPS at -6.2, the market is not valuing earnings because there are none to value; instead, investors are underwriting a pipeline optionality story against a $1,382M market cap. The Altman Z-Score of 26.8 and a Current Ratio of 14.6 indicate extraordinary short-term solvency and negligible bankruptcy risk, which is rare for a company posting an operating margin of -34.40% and ROIC of -33.90%. This is not a classic growth-at-a-reasonable-price situation—it’s a high-liquidity, high-burn biotech where safety comes from cash reserves, not cash generation.

AI Exposure / Tech Reliance

As a Biotechnology company in Healthcare listed on Nasdaq, BCAX operates in an industry increasingly shaped by AI-driven drug discovery and data-centric clinical development. The sector’s evolution toward computational biology and precision medicine creates structural incentives for firms to adopt advanced analytics. Its ability to remain relevant will hinge on integrating modern R&D technologies to compress development timelines and improve clinical hit rates.

The Bull Case

A speculative GARP investor could argue the balance sheet strength is the hidden asset here. A Current Ratio of 14.6 combined with an Altman Z-Score of 26.8 signals a fortress liquidity position, dramatically lowering near-term financial distress risk despite negative profitability. Institutional ownership at 31.50% suggests some level of professional sponsorship, and the consensus target price of 1.43 alongside a consensus rating of 20.80% implies asymmetric upside if pipeline execution improves. For investors who specialize in early-stage biotech optionality, the absence of leverage metrics and the company’s ability to fund operations internally may justify underwriting current operating losses in exchange for potential inflection.

The Bear Case

The bear case is blunt: this is a capital-consuming enterprise with no earnings, no forward earnings visibility, and deteriorating economics. EPS of -6.2, projected EPS next year of -2.52, operating margin of -34.40%, and ROIC of -33.90% collectively describe a business that destroys capital at the operating level. The Piotroski F-Score of 1 is a flashing red signal of extremely weak financial quality, while missing PEG Forward and Debt/Equity metrics eliminate visibility into growth efficiency and leverage discipline. Sales Growth Next Year at -$3.04 further reinforces the absence of a near-term revenue engine, making the $1,382M valuation entirely dependent on speculative future breakthroughs rather than demonstrated execution.

Market Sentiment & Smart Money

Short Interest %

20.80%

Analyst Consensus

1.43

Average Analyst Price Target

$31.50

Institutional Ownership %

88.40%

1-Year Beta

1.67

Insider Buying % (6 Mo)

10.30%%

Distance to 52-Week High

96.00%%

Distance to 52-Week Low

270.80%%